As opposed to VHL inactivation, a known founding event of ccRCC, mutations in genes involved in disease progression such as PBRM1, BAP1, and SETD2 are associated with aggressive clinical features [14–16]. Here, SETD2 is linked to nonpapillary renal cell carcinoma.